Combined modality adjuvant therapy for high-risk endometrial cancer
نویسندگان
چکیده
منابع مشابه
Adjuvant postoperative combined-modality therapy for rectal cancer.
A number of advances have been made in the use of adjuvant chemotherapy for resectable rectal cancer. Whereas pelvic radiation therapy has been shown to increase local control in patients with clinically resectable disease, systemic chemotherapy is needed in addition to further improve local control and overall survival. In this review, the experience treating patients with clinically resectabl...
متن کاملAdjuvant therapy for endometrial cancer
Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for ea...
متن کاملPrimary combined-modality therapy for esophageal cancer.
Based on positive results from the Radiation Therapy Oncology Group (RTOG) 85-01 trial, the conventional nonsurgical treatment of esophageal carcinoma is combined-modality therapy. Dose intensification of the RTOG 85-01 regimen, examined in the Intergroup (INT)-0123/RTOG 94-05 trial, did not improve local control or survival. Areas of clinical investigation include the development of combined-m...
متن کامل[Combined-modality therapy for lung cancer].
Lung cancer is treated with surgery, radiotherapy and chemotherapy according to histology and clinical stage. Advanced stage lung cancer patients cannot be cured, but early and locally-advanced stage patients can be cured by intensive combined-modality therapy. Combined-modality therapy with surgery plus adjuvant chemotherapy is standard for resectable IB-IIIA non-small cell lung cancer (NSCLC)...
متن کاملCombined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
BACKGROUND To report the outcomes of patients treated with combined iodine-125 (I-125) brachytherapy and external beam radiotherapy (EBRT) for high-risk prostate cancer. METHODS Between 2003 and 2009, I-125 permanent prostate brachytherapy plus EBRT was performed for 206 patients with high-risk prostate cancer. High-risk patients had prostate-specific antigen ≥ 20 ng/mL, and/or Gleason score ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Oncology
سال: 2016
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(16)30152-8